News articles about Sienna Biopharm (NASDAQ:SNNA) have trended somewhat positive recently, according to Accern. The research firm identifies negative and positive news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Sienna Biopharm earned a daily sentiment score of 0.18 on Accern’s scale. Accern also gave news stories about the company an impact score of 46.2869461141828 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Shares of Sienna Biopharm (NASDAQ SNNA) traded up 0.21% during mid-day trading on Wednesday, hitting $24.30. 121,464 shares of the company were exchanged. Sienna Biopharm has a 12-month low of $18.50 and a 12-month high of $29.25. The company’s 50-day moving average price is $21.48 and its 200-day moving average price is $21.48.

A number of analysts recently weighed in on the stock. Cowen and Company assumed coverage on shares of Sienna Biopharm in a report on Monday, August 21st. They issued an “outperform” rating and a $50.00 price target for the company. J P Morgan Chase & Co assumed coverage on shares of Sienna Biopharm in a report on Monday, August 21st. They issued an “overweight” rating and a $28.00 price target for the company. Finally, BMO Capital Markets assumed coverage on shares of Sienna Biopharm in a report on Monday, August 21st. They issued an “outperform” rating and a $30.00 price target for the company.

COPYRIGHT VIOLATION WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Sienna Biopharm (SNNA) Share Price” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international copyright & trademark laws. The original version of this piece can be read at https://www.thecerbatgem.com/2017/09/06/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-sienna-biopharm-snna-share-price.html.

In related news, CFO Richard D. Peterson purchased 7,000 shares of Sienna Biopharm stock in a transaction on Tuesday, August 1st. The stock was acquired at an average cost of $15.00 per share, for a total transaction of $105,000.00. Following the completion of the acquisition, the chief financial officer now owns 7,000 shares of the company’s stock, valued at approximately $105,000. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Keith R. Leonard purchased 16,700 shares of Sienna Biopharm stock in a transaction on Tuesday, August 1st. The stock was bought at an average price of $15.00 per share, with a total value of $250,500.00. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 48,700 shares of company stock valued at $730,500.

Sienna Biopharm Company Profile

Sienna Biopharmaceuticals, Inc is a United States-based medical dermatology and aesthetics company. The Company focuses on developing targeted therapies to treat inflammatory skin conditions and aesthetic concerns that impact the health and appearance of patients. Its research and clinical-stage candidates include programs, such as SNA-001, SNA-120 and SNA-125.

Receive News & Stock Ratings for Sienna Biopharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sienna Biopharm and related stocks with our FREE daily email newsletter.